Place in therapy of olmesartan

Qual è il Giusto Place in Therapy Dell'olmesartan?

Authors

  • Antonio Addis Dipartimento Epidemiologia del S.S.R. del Lazio, ASL Roma1, Roma - Italy
  • Francesco Trotta Dipartimento Epidemiologia del S.S.R. del Lazio, ASL Roma1, Roma - Italy

DOI:

https://doi.org/10.33393/grhta.2017.388

Keywords:

Angiotensin receptor blockers, Drug expenditure, Drug utilization, Olmesartan, Place in therapy, Post-marketing safety

Abstract

Olmesartan has been de-reimbursed in France since January 2017 following a negative evaluation of its benefit/risk profile compared with other sartans. However, olmesartan is one of the antihypertensive blockbusters in Italy in terms of usage and expenditure. This article illustrates the pathway leading to a critical appraisal issued by the Lazio Regional Committee for Medicines with the aim of promoting the rational use of olmesartan and its place in therapy. Moreover, this short communication offers potential scenarios to combine the use of evidence-based information about a widely prescribed antihypertensive drug with cost considerations related to the entire class of sartans.

Most read articles by the same author(s)